Stock TNYA TENAYA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Tenaya Therapeutics, Inc.

Equities

TNYA

US87990A1060

Market Closed - Nasdaq
Other stock markets
 01:30:00 27/04/2024 am IST 		5-day change 1st Jan Change
4.31 USD +2.13% Intraday chart for Tenaya Therapeutics, Inc. -0.23% +33.02%
20/03 Canaccord Genuity Adjusts Price Target on Tenaya Therapeutics to $18 From $19, Maintains Buy Rating MT
19/03 North American Morning Briefing : Stock Futures -2- DJ

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Canaccord Genuity Adjusts Price Target on Tenaya Therapeutics to $18 From $19, Maintains Buy Rating
MT
North American Morning Briefing : Stock Futures -2-
DJ
Tenaya Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
AQ
Tenaya Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine
AQ
Tenaya Therapeutics, Inc. Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine
CI
Transcript : Tenaya Therapeutics, Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-12-2024 08:40 AM
Tenaya Therapeutics to Participate in Upcoming March Investor Conferences
AQ
Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications
AQ
Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications
CI
Tenaya Therapeutics Insider Bought Shares Worth $9,999,999, According to a Recent SEC Filing
MT
Tenaya Therapeutics Announces Pricing of Underwritten Offering
AQ
Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
AQ
Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference
AQ
Tenaya Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
AQ
Tenaya Therapeutics Gets FDA Clearance For TN-401 Gene Therapy Trial
MT
Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
AQ
Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TNYA Stock
  4. News Tenaya Therapeutics, Inc.